5-Year Radiographic Outcomes With Risankizumab in Psoriatic Arthritis: KEEPsAKE 1 Data

Saakshi Khattri, MD, reviews 5-year extension data of risankizumab in psoriatic arthritis, emphasizing sustained radiographic non-progression and durability of clinical response.

In this portion of the conversation, Saakshi Khattri, MD, examines long-term efficacy data from the phase 3 KEEPsAKE 1 trial of risankizumab in psoriatic arthritis. She notes that KEEPsAKE 1 is a randomized, controlled study evaluating risankizumab 150 mg every 12 weeks (after loading doses 4 weeks apart) in patients with active PsA. The primary endpoint at week 24 was met, providing robust short-term evidence of clinical efficacy and supporting risankizumab’s role as a therapeutic option in PsA.

Khattri then focuses on the long-term extension data, which now extend out to 5 years. These data show that a high proportion of patients maintained radiographic non-progression over time, with no substantial worsening in modified total Sharp scores, which capture both erosions and joint space narrowing.

In addition, key clinical outcomes—including American College of Rheumatology (ACR) response measures—demonstrated durability, suggesting that many patients maintained meaningful symptom control and functional benefit across the 5-year period.

From a clinical standpoint, Khattri emphasizes that PsA is a chronic, progressive condition in which cumulative, irreversible structural damage can lead to long-term disability. Accordingly, sustained inhibition of radiographic progression is a critical outcome for both clinicians and patients.

She acknowledges the usual caveats of long-term extension studies—namely, that patients who remain on therapy are often those doing well—but nonetheless considers the 5-year radiographic and clinical durability data with risankizumab to be highly relevant when discussing long-term treatment expectations with patients.